Table 3.
Clinical trials studying on CDK4/6 inhibitors in combination with other therapies in other cancer treatment.
| Disease | Combination | Phase | Trial |
|---|---|---|---|
| Palbociclib | |||
| KRAS mutant non-small-cell lung cancer, solid tumors | PD-0325901(MEK inhibitor) | I/II | NCT02022982 |
| Squamous cell carcinoma of the head and neck (SCCHN) | Cetuximab | II | NCT02499120 |
| Squamous cell carcinoma of the head and neck | Carboplatin | II | NCT03194373 |
| Recurrent mantle cell lymphoma | Ibrutinib (BTK Inhibitor) | I | NCT02159755 |
| Advanced solid tumors, breast cancer | Taselisib or pictilisib (PI3K inhibitor) | I | NCT02389842 |
| Endometrial cancer | Letrozole | II | NCT02730429 |
| Ovarian epithelial carcinoma | II | NCT01536743 | |
| Advanced solid tumor malignancies | 5-FU and oxaliplatin | I | NCT01522989 |
| Palbociclib | |||
| Advanced hepatocellular carcinoma, | II | NCT01356628 | |
| HCC, liver cancer | |||
| Non-small-cell lung cancer | PF-06747775 and avelumab | II | NCT02349633 |
| Ribociclib | |||
| Glioblastoma glioma | I | NCT02345824 | |
| Acute lymphoblastic leukemia ALL | Dexamethasone and everolimus | I | NCT03740334 |
| High grade glioma, | I/II | NCT02607124 | |
| Diffuse intrinsic pontine glioma, | |||
| Bithalamic high grade glioma | |||
| Gastrointestinal cancer | II | NCT02420691 | |
| Metastatic pancreatic | Everolimus | II | NCT02985125 |
| Ribociclib | |||
| Adenocarcinoma | |||
| Liposarcoma | HDM201 | I/II | NCT02343172 |
| Solid tumors harboring | LGX818 and MEK162 | I/II | NCT01543698 |
| Abemaciclib | |||
| Glioblastoma | II | NCT02981940 | |
| Non-small-cell lung cancer stage IV | Docetaxel | II | NCT02450539 |
| Non-small-cell lung cancer | Erlotinib | III | NCT02152631 |
| Non-small-cell lung cancer | Pembrolizumab and anastrozole | I | NCT02779751 |
| Breast cancer, mantle cell lymphoma | II | NCT01739309 | |